{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibvqia3on4ij2pjjhn7fijcr7vb536i4f3xp7b532nnrl4p76rlwu",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mhhk75whs2v2"
  },
  "path": "/2026/03/20/alphamab-oncology-announces-the-first-patient-dosed-in-a-phase-iii-clinical-study-for-triple-negative-breast-cancer-of-trop2-her3-bispecific-adc-jskn016/",
  "publishedAt": "2026-03-20T02:04:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SUZHOU, China, March 20, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC). This milestone brings another innovative bispecific ADC from the company’s pipeline into […]",
  "title": "Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016"
}